CastrationResistant

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary…

TUESDAY, June 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated,…

Elana Gotkine FRIDAY, Feb. 17, 2023 (HealthDay News) -- For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of…

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway…

Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA submissions NEW YORK and VIENNA, Austria, July…

New York, USA, July 11, 2022 (GLOBE NEWSWIRE) -- Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights | DelveInsight Metastatic castration-resistant prostate cancer (CRPC) is a form of advanced prostate…

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell…